Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

109 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication?
Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahlen A, Agurell S. Hollister LE, et al. J Clin Pharmacol. 1981 Aug-Sep;21(S1):171S-177S. doi: 10.1002/j.1552-4604.1981.tb02593.x. J Clin Pharmacol. 1981. PMID: 6271822
This lag between plasma concentration and "high" continued during most of the span of the drug's effects. The situation was quite similar following smoking, except that peak plasma concentrations were lower. ...
This lag between plasma concentration and "high" continued during most of the span of the drug's effects. The situation was quite sim …
Relative pharmacological potency in mice of optical isomers of delta 1-tetrahydrocannabinol.
Jones G, Pertwee RG, Gill EW, Paton WD, Nilsson IM, Widman M, Agurell S. Jones G, et al. Biochem Pharmacol. 1974 Jan 15;23(2):439-46. doi: 10.1016/0006-2952(74)90435-3. Biochem Pharmacol. 1974. PMID: 4813356 No abstract available.
Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.
Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Ohlsson A, et al. Clin Pharmacol Ther. 1980 Sep;28(3):409-16. doi: 10.1038/clpt.1980.181. Clin Pharmacol Ther. 1980. PMID: 6250760
Urinary metabolites of delta 1-tetrahydrocannabinol in man.
Halldin MM, Carlsson S, Kanter SL, Widman M, Agurell S. Halldin MM, et al. Among authors: agurell s. Arzneimittelforschung. 1982;32(7):764-8. Arzneimittelforschung. 1982. PMID: 6289845
Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users.
Ohlsson A, Lindgren JE, Wahlén A, Agurell S, Hollister LE, Gillespie HK. Ohlsson A, et al. Among authors: agurell s. Biomed Mass Spectrom. 1982 Jan;9(1):6-10. doi: 10.1002/bms.1200090103. Biomed Mass Spectrom. 1982. PMID: 6277407
Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis.
Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H. Lindgren JE, et al. Psychopharmacology (Berl). 1981;74(3):208-12. doi: 10.1007/BF00427095. Psychopharmacology (Berl). 1981. PMID: 6267648 Clinical Trial.
Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.
Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK. Johansson E, et al. Among authors: agurell s. Eur J Clin Pharmacol. 1989;37(3):273-7. doi: 10.1007/BF00679783. Eur J Clin Pharmacol. 1989. PMID: 2558889
Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography.
Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. Agurell S, et al. Experientia. 1981 Oct 15;37(10):1090-2. doi: 10.1007/BF02085029. Experientia. 1981. PMID: 6273208 No abstract available.
109 results
Jump to page
Feedback